Evidência

Tabelas de evidência

Esta tabela é um sumário da análise relatada em uma Resposta Clínica Cochrane que enfoca a importante questão clínica acima.


A confiança na evidência é alta ou moderada a alta onde GRADE foi realizado e a intervenção é mais eficaz/benéfica do que a comparação para os principais desfechos.


População: Adultos com DPOC moderada a grave

Intervenção: Umeclidínio (uma vez ao dia via inalador de pó seco por 12-52 semanas)

Comparação: Placebo

DesfechoEficácia (classificação do BMJ)?Confiança na evidência (GRADE)?

Número de participantes com exacerbações exigindo corticosteroides, antibióticos ou ambos em 52 semanas

Intervenção favorável

Alto

Qualidade de vida em 24-52 semanas (medida pelo St George´s Respiratory Questionnaire [SGRQ])

Intervenção favorável

Moderado

Número de participantes com internação hospitalar devida a exacerbação da DPOC em 52 semanas (medido pelo Índice de Dispneia Transicional [TDI])

Nenhuma diferença estatisticamente significativa

Baixo

Melhora dos sintomas em 24 semanas

Intervenção favorável

Alto

Função pulmonar em 4-52 semanas

Intervenção favorável

Alto

Eventos adversos graves não fatais

Nenhuma diferença estatisticamente significativa

Moderado

Eventos adversos

Nenhuma diferença estatisticamente significativa

Moderado

Esta tabela de evidências está relacionada às seguintes seções:

Respostas Clínicas Cochrane

  • What are the effects of integrated disease management (IDM) interventions for people with chronic obstructive pulmonary disease (COPD)?
    Show me the answer
  • How does umeclidinium bromide compare with placebo for people with chronic obstructive pulmonary disease (COPD)?
    Show me the answer
  • How does long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) compare with LABA plus inhaled corticosteroid (ICS) for people with stable chronic obstructive pulmonary disease (COPD)?
    Show me the answer
  • How does tiotropium compare with ipratropium bromide for people with chronic obstructive pulmonary disease (COPD)?
    Show me the answer
  • How does a combined inhaler with once‐daily long‐acting beta2‐agonist (LABA) plus a long‐acting muscarinic antagonist (LAMA) compare with placebo for adults with chronic obstructive pulmonary disease (COPD)?
    Show me the answer
  • What are the longer-term (>6 months) effects of inhaled corticosteroids in people with stable chronic obstructive pulmonary disease?
    Show me the answer
  • What are the effects of long‐acting inhaled therapies for adults with chronic obstructive pulmonary disease (COPD)?
    Show me the answer
  • In people with chronic obstructive pulmonary disease (COPD), what are the effects of combined corticosteroid and long-acting beta-agonist (LABA) in one inhaler versus LABA alone?
    Show me the answer
  • What are the effects of prophylactic antibiotics for people with chronic obstructive pulmonary disease (COPD)?
    Show me the answer
  • What are the effects of influenza vaccine in people with chronic obstructive pulmonary disease (COPD)?
    Show me the answer
  • For people with chronic bronchitis or chronic obstructive pulmonary disease, how do mucolytic agents compare with placebo?
    Show me the answer
  • What are the effects of pulmonary rehabilitation after exacerbation in people with chronic obstructive pulmonary disease?
    Show me the answer
  • How does bronchoscopic lung volume reduction compare with medical therapy in people with chronic obstructive pulmonary disease?
    Show me the answer
  • How do statins compare with placebo for people with chronic obstructive pulmonary disease (COPD)?
    Show me the answer
  • How does combined aclidinium/formoterol compare with aclidinium or formoterol monotherapy for people with chronic obstructive pulmonary disease (COPD)?
    Show me the answer
  • How does lung volume reduction surgery compare with usual medical care in people with diffuse emphysema?
    Show me the answer

O uso deste conteúdo está sujeito ao nosso aviso legal